Forum Topic News
  • Conversation: Celgene to buy Juno Therapeutics for $9bn

    • January 24, 2018 1:41 PM GMT
      • Post(s)

      Celgene to buy Juno Therapeutics for $9bn

      Celgene has signed an agreement to acquire integrated biopharmaceutical firm Juno Therapeutics for around $9bn.
      Under the deal, Celgene will purchase Juno’s stock by paying $87 per share in cash.
      Juno is engaged in the development of novel cellular immunotherapies for the treatment of cancer.
      The company has developed cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to distinguish and kill cancer.
      The acquisition will add JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene's lymphoma program. It is a CD19-directed CAR T currently in a pivotal program for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
      In the US, JCAR017 is expected to receive approval in 2019.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel